| 2006D-0347 | Guidance for Industry, Clinical Laboratories, and FDA Staff on In Vitro Diagnostic Multivariate Index Assays | |||||||||||||||||||||||
| FDA Comment Number : | EC5 | |||||||||||||||||||||||
| Submitter : | Dr. Roland Stoughton | Date & Time: | 10/18/2006 10:10:41 | |||||||||||||||||||||
| Organization : | GHC Technologies, Inc. | |||||||||||||||||||||||
| Category : | Device Industry | |||||||||||||||||||||||
| Issue Areas/Comments | ||||||||||||||||||||||||
| GENERAL | ||||||||||||||||||||||||
| GENERAL | ||||||||||||||||||||||||
| In the second of the three characteristics listed as defining IVDMIAs, is the word "proprietary" essential? In other words, if all the information were publicly published, but the other criteria were met, would the assay still be an IVDMIA? | ||||||||||||||||||||||||